 |
Dale A. Stringfellow, Ph.D. Joins Acologix’s
Board of Directors
Emeryville, CA-May 27, 2004 — Acologix, Inc., a privately
held biopharmaceutical company, today announced the addition of
a key member to its team. Dr. Dale A. Stringfellow has joined Acologix's
Board of Directors. "We are very pleased to have Dr. Stringfellow,
who brings over 30 years of experience in the pharmaceutical industry,
to the Acologix’s Board of Directors," said Mr. Yoshi
Kumagai, President and CEO of Acologix. "Throughout his career,
Dr. Stringfellow has held top management positions and managed a
wide array of products at leading pharmaceutical and biotech companies
in the U.S. We are confident his expertise in research and development
will strengthen Acologix's ability to move its drug candidates through
clinical trials toward market approval."
Dr. Stringfellow most recently served as President and CEO of Berlex,
the U.S. pharmaceutical division of Schering AG, Germany from 2000
to April 2003, where he oversaw the introduction of six significant
new products to the market for Berlex during his tenure. From 1995
to 2000, Dr. Stringfellow was President of Berlex Biosciences which
is responsible for all of Schering's research and development in
the U.S. From July 1990 until April 1995, he was President, CEO
and a Director of Celtrix Pharmaceuticals. Dr. Stringfellow has
also held other senior positions including: Vice President and Senior
Director of Preclinical Cancer Research at Bristol-Myers Company;
Research Head, Cancer Virology and Cellular Biology Research at
Upjohn Company; and Vice President, Research and Development at
Collagen Corporation.
Dr. Stringfellow currently serves as Chairman of the Board of Myriad
Genetics, Inc.
Dr. Stringfellow received a B.S. and a Ph.D. in Microbiology from
the University of Utah.
About Acologix, Inc.
Acologix, Inc., based in Emeryville, Calif., is a privately held
biopharmaceutical company focused on developing and commercializing
novel therapeutics primarily for the treatment of metabolic disorders
of kidney and bone that comprise significant unmet medical needs.
Founded in 1992, the company’s research is centered on the
body’s metabolism of minerals and extracellular matrix molecules
that form the biological scaffold for bone and connective tissue.
This has led to the identification of unique therapeutic candidates
for product development and commercialization. Acologix is seeking
strategic development, commercial partnerships and licensees with
pharmaceutical and biotechnology companies for several of its programs.
This press release contains “forward-looking” statements.
These statements involve risks and uncertainties, which may cause
results to differ materially from those set forth in the statements.
The forward-looking statements include statements regarding product
development and cannot be guaranteed. Acologix undertakes no obligation
to publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise. Forward-looking
statements in this press release should be evaluated together with
the many uncertainties that affect Acologix’s business.
Company Contact
Yoshi Kumagai
President & CEO
Phone: 510.379.1073 ext 10
Fax: 510.379.1074
| |
|
| |
|
